Childhood Acute Lymphoblastic Leukemia Clinical Trials

2 recruiting

Frequently Asked Questions

Common questions about Childhood Acute Lymphoblastic Leukemia clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting
Phase 1

Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAcute Leukemia+5 more
City of Hope Medical Center27 enrolled1 locationNCT06575296
Recruiting
Phase 1

Clinical Trial of CMD63 Chimeric Antigen Receptor T-cell (CAR T-cell) in Children With Acute Lymphoblastic Leukemia (ALL)

Refactory Childhood Acute Lymphoblastic LeukemiaRelapse B Acute Lymphoblastic Leukemia
Chulalongkorn University16 enrolled3 locationsNCT07078929
Recruiting

A Multi-site Study to Evaluate the Persistence of Protective Immunity to Routine Childhood Vaccinations in Participants With B-ALL/Ly Who Have Received Blinatumomab

B-cell Acute Lymphoblastic LeukemiaB-Cell Lymphoblastic LeukemiaB-cell Acute Lymphoblastic Leukemia (B-ALL)+5 more
Arkansas Children's Hospital Research Institute300 enrolled2 locationsNCT07422337
Recruiting

Exploring the Effect of Calaspargase Pegol on the Coagulation System in Pediatric Acute Lymphoblastic Leukemia (ALL) Patients: Pilot Study

Childhood Acute Lymphoblastic LeukemiaChildhood Lymphoblastic Lymphoma
Mayo Clinic15 enrolled1 locationNCT07071051
Recruiting
Phase 1

HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaChronic Myeloid Leukemia+26 more
Fred Hutchinson Cancer Center24 enrolled1 locationNCT03326921
Recruiting
Phase 1

Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling

Recurrent Childhood Lymphoblastic LymphomaRecurrent Childhood Acute Myeloid LeukemiaRefractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive+15 more
Florida International University65 enrolled1 locationNCT05857969
Recruiting
Phase 1

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

Recurrent Chronic Lymphocytic LeukemiaRefractory Chronic Lymphocytic LeukemiaRecurrent Non-Hodgkin Lymphoma+15 more
Sumithira Vasu54 enrolled2 locationsNCT05418088
Recruiting
Phase 2

Blinatumomab After TCR Alpha Beta/CD19 Depleted HCT

B-cell Acute Lymphoblastic LeukemiaB-cell Childhood Acute Lymphoblastic LeukemiaB-Cell ALL, Childhood
Medical College of Wisconsin25 enrolled1 locationNCT04746209